The Clinical and Experimental Therapeutics Program (Program 4) is a cohesive, integrated program supported by $7,523,204 (annual direct costs) in peer-reviewed funding, with $3,613,675 from the NCI. There are 47 members representing nine departments. Of the total 747 member peer-reviewed publications during the current grant cycle, 216 (29%) represent intraprogrammatic, and 145 (19%) represent interprogrammatic collaborations. The overall goal of the Program is to foster interaction between basic and clinical investigators that will result in innovative and effective therapies for cancer patients. The translational nature of much of the work emanating from this program and the leadership role assumed by many program faculty in studies conducted by national clinical trials cooperative groups illustrates the impact of this program in developing new therapies for oncology. The Program has a long-standing focus on drug development at all phases of clinical testing and a strong pharmacogenetic component. Trials span the gamut from preclinical development to investigator-initiated Phase I clinical trials, to Phase II trials in the regional Phase II network to Phase III studies within CALGB. They incorporate correlative laboratory studies including pharmacokinetic studies, genotyping studies, population pharmacology, pharmacogenetic studies, and the measurement of surrogate endpoints. Clinical trials are conducted by multidisciplinary teams comprised of a group of clinical investigators representing Medical Oncology, Radiation Oncology, Pathology, and appropriate surgical specialties. Clinical efforts focus on studies of new drugs (cytotoxic or cytostatic) with clinical and translational endpoints, modulation of current chemotherapy, sequencing of multidisciplinary treatment, organ preservation, transplantation, and treatment intensification as strategies to increase cure rates and response. Imaging, surgical, and pathology support are integrated into the Program. The scientific goals are (1) to foster interaction between basic and clinical investigators that will result in innovative and effective therapies;(2) to integrate new drugs into the development of multimodality therapies for patients with advanced solid tumors;and (3) to pursue a broad program of preclinical, translational, and clinical research in pharmacogenetics and pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-37
Application #
8375695
Study Section
Special Emphasis Panel (ZCA1-RTRB-N)
Project Start
Project End
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
37
Fiscal Year
2012
Total Cost
$38,519
Indirect Cost
$13,466
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Sharifi, Marina N; Mowers, Erin E; Drake, Lauren E et al. (2016) Autophagy Promotes Focal Adhesion Disassembly and Cell Motility of Metastatic Tumor Cells through the Direct Interaction of Paxillin with LC3. Cell Rep 15:1660-72
Drazer, Michael W; Stadler, Walter M (2016) The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer. Cancer J 22:330-333
Epel, Boris; Redler, Gage; Pelizzari, Charles et al. (2016) Approaching Oxygen-Guided Intensity-Modulated Radiation Therapy. Adv Exp Med Biol 876:185-93
Sweis, Randy F; Medved, Milica; Towey, Shannon et al. (2016) Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer :
Volden, Paul A; Skor, Maxwell N; Johnson, Marianna B et al. (2016) Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor-Negative Mammary Epithelial Cell Proliferation. Cancer Prev Res (Phila) 9:367-78
Stein, Michelle M; Hrusch, Cara L; Gozdz, Justyna et al. (2016) Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med 375:411-21
Baron, Beverly W; Baron, Rebecca M; Baron, Joseph M (2016) The Relationship between RUVBL1 (Pontin, TIP49, NMP238) and BCL6 in Benign and Malignant Human Lymphoid Tissues. Biochem Biophys Rep 6:1-8
King, Andrea C; Hasin, Deborah; O'Connor, Sean J et al. (2016) A Prospective 5-Year Re-examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder. Biol Psychiatry 79:489-98
Appelbe, Oliver K; Zhang, Qingbei; Pelizzari, Charles A et al. (2016) Image-Guided Radiotherapy Targets Macromolecules through Altering the Tumor Microenvironment. Mol Pharm 13:3457-3467
Morrison, Gladys; Lenkala, Divya; LaCroix, Bonnie et al. (2016) Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget 7:38359-38366

Showing the most recent 10 out of 534 publications